Impact of Treatment Time on Outcome for Resected Head and Neck Squamous Cell Carcinoma by HPV Status

Nicholas S. Andresen¹, Anthony N. Snow², Sarah L. Mott³, Nitin A. Pagedar⁴, Rodrigo Bayon⁴, Carryn M. Anderson¹, John M. Buatti¹ and John M. Watkins¹*

¹University of Iowa, Department of Radiation Oncology, Iowa City, Iowa, USA
²University of Iowa, Department of Pathology, Iowa City, Iowa, USA
³Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA
⁴University of Iowa, Department of Otolaryngology-Head & Neck Surgery, Iowa City, Iowa, USA

BACKGROUND AND PURPOSE: Prior investigations have demonstrated an inverse correlation between the interval from resection of head and neck squamous cell carcinoma (HNSCC) to radiotherapy (RT) completion (overall treatment time; OTT) and disease control. However, the importance of OTT in human papillomavirus (HPV)-associated HNSCC remains to be determined. This study evaluates whether OTT remains independently associated with cancer control when evaluated by HPV association.

MATERIAL AND METHODS: The data of HNSCC patients treated with curative-intent surgical resection followed by RT were collected. Univariable and multivariable analyses were used to assess the effects of HPV association and OTT.

RESULTS: From 2002-2014, 73 eligible patients were identified (36 HPV-associated). The median OTT was 94 days (range, 69-185, with no difference between HPV subgroups). At a median follow-up of 34.9 months (range, 2.6-162.2), 21 patients experienced disease failure, and 25 died. HPV-association was linked to improved disease-free survival (DFS), disease-specific survival (DFS), and overall survival (OS) by univariable and multivariable analyses. OTT was associated with improved DFS by univariable and multivariable analyses.

CONCLUSION: OTT remains significantly associated with cancer control in the setting of HPV-associated disease. Efforts should be made to minimize the delay between resection and completion of RT for all HNSCC patients.

© 2020 John M. Watkins. Hosting by Science Repository. All rights reserved.
While staging and treatment regimens are in the process of being modified to adapt to the changing demographics of HNSCC, HPV-associated tumors are currently managed according to traditional standards-of-care. This standard of care commonly includes surgical resection and radioadjuvant therapy with attention to avoid a prolonged OTT. As the impact of OTT in this context remains undetermined, the present study seeks to determine whether OTT remains independently associated with cancer control in the setting of HPV-associated disease.

Materials and Methods

A single-institution retrospective analysis was performed for patients with non-metastatic HNSCC from the oral cavity or the oropharyngeal primary sites between 2002 and 2014 and treated with curative-intent surgical resection and adjuvant RT (with or without chemotherapy, as indicated). All patients received standard fractionation RT (1.8-2 Gy, once daily, 5 days per week). Patients who received preoperative chemotherapy, did not have tumor HPV data, had incomplete RT records or completion of <90% of the prescribed RT dose or follow-up of less than 12 months post-resection were excluded. Tumor HPV status was determined by p16 immunohistochemistry (IHC), polymerase chain reaction (PCR), or high-risk DNA in situ hybridization (ISH). The use of concurrent chemotherapy was recorded and included in the analysis. Data for each patient was extracted from medical records and verified separately by two investigators.

Chi-square tests, Fisher’s exact tests, and Wilcoxon rank sum tests were used to investigate differences between the HPV negative and HPV positive groups. Groups were compared based upon demographics (e.g., age at diagnosis, gender, tobacco use), staging workup (e.g., PET/CT), tumor characteristics (e.g., grade, clinical and pathologic American Joint Committee on Cancer (AJCC) stages, margin status, perineural invasion, lymphovascular invasion, nodal involvement, extracapsular extension), treatment characteristics (e.g., OTT, RT dose, chemotherapy), and follow-up [16]. Overall treatment time was calculated from the date of resection to the end of radiotherapy.

Cox regression models were used to assess the effects of demographic, staging work-up, tumor characteristics, and treatment variables on disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). DFS was calculated from the date of resection to the initial date of clinical or radiographic recurrence, or at last clinical follow-up or death, if no recurrence had occurred. DSS and OS were calculated from the date of resection to the date of death, with events for DSS recorded if death occurred in the context of known recurrence. For patients who died >3 months after their last clinical evaluation (unknown disease status), DFS and DSS were calculated to the date of the last clinical follow-up without recorded event. Due to the limited number of events, only HPV status and OTT were evaluated in the multivariable model. Estimated effects of predictors were calculated as hazard ratios (HR) with 95% confidence intervals.

The Kaplan-Meier method was used to calculate four-year estimates of DFS, DSS, and OS for the entire population, and for HPV and OTT subgroups. Estimates, along with 95% pointwise confidence intervals, were reported. All statistical testing was two-sided and assessed for significance at the 5% level using SAS software (Cary, NC, U.S.A.). This study was approved by the University of Iowa Institutional Review Board.

Table 1: Demographic, clinical, and pathologic characteristics of entire cohort.

| Characteristic                  | Median (Range) | n (%)   |
|--------------------------------|----------------|---------|
| Age                            | 59 years (29-82) | 73      |
| Gender                         |                |         |
| Female                         | 20 (27)        |         |
| HPV Status                     |                |         |
| Positive                       | 36 (49)        |         |
| Primary Site                   |                |         |
| Oral Cavity                    | 35 (48)        |         |
| Oropharynx                     | 38 (52)        |         |
| Tobacco Use History            |                |         |
| None                           | 21 (29)        |         |
| ≤10 pack-years                 | 12 (17)        |         |
| >10 pack-years                 | 39 (54)        |         |
| PET/CT Staging                 | 53 (72)        |         |
| AJCC Clinical Stage            |                |         |
| 1-2                            | 15 (20)        |         |
| 3                              | 23 (31)        |         |
| 4a                             | 35 (48)        |         |
| Interval, Biopsy to Resection  | 35 days (0-90) |         |
| TORS approach                  | 22 (30)        |         |
| Tumor Grade                    |                |         |


### Results

Between 2002 and 2014, a total of 98 patients were identified for inclusion, of whom 73 were eligible for the present analysis. Reasons for exclusion were: incomplete RT records (n=10), completion of <90% of RT dose (4), missing tumor HPV data (4), insufficient follow-up (4), receipt of preoperative chemotherapy (2), and metastasis at diagnosis (1). Within the 73 patient study population, 20 (27%) were female, 58 (80%) had AJCC clinical stage III-IV disease, 36 (49%) had HPV-associated tumors, and the median OTT was 94 days (range, 69-185, with no difference between HPV subgroups).

For HPV-associated tumors, the determination was made by p16 IHC in 31 cases, PCR in 1 case, high-risk DNA ISH in 2 cases, and multiple techniques in 2 cases. Detailed patient population characteristics are demonstrated in (Table 1). Differences between the HPV groups are outlined in (Table 2), with HPV-associated tumors more likely to be male, have a limited (or no) tobacco use history, PET/CT staging, oropharynx primary site, higher stage disease at diagnosis, shorter interval from biopsy to surgery, higher-grade tumors, smaller primary tumor size, larger maximal lymph node dimension, and lower rates of perineural invasion (Table 2). Of note, 34 of 38 oropharynx primary cases were HPV-associated, as compared with 2 of 35 oral cavity cases.

At a median follow-up of 34.9 months (range, 2.6-162.2) for all patients and 40.8 months for surviving patients (with 37.5% followed >4 years), 21 patients (28%) experienced disease failure, and 25 (34%) died (17 due to HNSCC). Univariable analysis for the total population demonstrated that higher AJCC clinical stage, oral cavity primary site, tumor grade, larger primary tumor size, and lack of HPV association were linked to worse DFS, DSS, and OS, while longer OTT was associated with lower DFS (Table 3; DSS data not shown). By multivariable analysis, HPV-association and shorter OTT remained significantly associated with improved DFS (Table 4; DSS data not shown). Survival curves with 4-year endpoint estimates for DFS and OS by HPV association and OTT (dichotomized to <100 versus >100 days) are demonstrated in (Figures 1a/1b & 2a/2b, respectively).

|                              | 1-2  | 3           | 43 (59) | 30 (41) |
|------------------------------|------|-------------|---------|---------|
| Tumor Size                   | 2.1 cm (0.3-6.7) | Pathologic Nodal Tumor Size (largest) | 2.2 cm (0.2-6.5) | Number LNs Involved | 2 (0-32) |
| Percent LNs Involved         | 6% (0-100) | Extranodal Extension | 37 (51) | Perineural Invasion | 31 (44) |
| Lymphovascular Invasion      | 33 (47) | Final Primary Margin Close (<1 mm) or Positive | 31 (42) |
| AJCC Pathologic Stage        | 1-3  | Concurrent Chemotherapy | 46.5 days (27-117) | Interval, Resection to RT | 6600 cGy (5000-7200) |
| AJCC Pathologic Stage        | 4    | Interval, RT Start to End | 46.5 days (31-111) | RT Dose | 94 days (69-185) |
| OTT                          |      | Disease Failure | 21 (29) | Survival Status | Alive | 48 (66) |
| OTT                          |      |              |        | Dead           | 25 (34) |
| Length of Follow-up          |      |              |        | 34.8 months (2-162) |

HPV: human papillomavirus; PET/CT: positron emission tomography/computed tomography; AJCC: American Joint Commission on Cancer; TORS: transoral robotic surgery; LNs: lymph nodes; RT: radiotherapy; OTT: overall treatment time.
Table 2: Demographic, clinical, and pathologic variables by HPV Status.

| Variable                              | HPV Negative n=37 | HPV Positive n=36 | p    |
|---------------------------------------|-------------------|-------------------|------|
| **Demographic**                       |                   |                   |      |
| Age Median (Range)                    | 56 yrs (29-82)    | 60 yrs (33-76)    | 0.74 |
| Gender                                |                   |                   |      |
| Female                                | 17 (46)           | 3 (8)             | <0.01|
| **Primary Site**                      |                   |                   |      |
| Oral Cavity                           | 33 (89)           | 2 (6)             | <0.01|
| Oropharynx                            | 4 (11)            | 34 (94)           |      |
| **Tobacco Use History**               |                   |                   |      |
| None                                  | 6 (16)            | 15 (43)           | 0.04 |
| ≤10 pack-years                        | 7 (19)            | 5 (14)            |      |
| >10 pack-years                        | 24 (65)           | 15 (43)           |      |
| **PET/CT Staging**                    | 22 (60)           | 31 (86)           | 0.01 |
| **AJCC Clinical Stage**               |                   |                   |      |
| 1-2                                   | 15 (40)           | 0 (0)             | <0.01|
| 3                                     | 13 (35)           | 10 (28)           |      |
| 4a                                    | 9 (24)            | 26 (72)           |      |
| **Interval, Biopsy to Resection**     | 39 days (7-90)    | 32 days (0-56)    | <0.01|
| **Tumor Grade**                       |                   |                   |      |
| 1-2                                   | 31 (84)           | 12 (33)           | <0.01|
| 3                                     | 6 (16)            | 24 (67)           |      |
| **Tumor Size**                        | 3.1 cm (0.9-6.7)  | 1.8 cm (0.3-4.7)  | <0.01|
| **Pathologic Nodal Tumor Size (largest)** | 1.25 cm (0.2-4.3) | 3.5 cm (0.9-6.5) | <0.01|
| **# LNs Involved**                    | 2 (0-5)           | 2 (1-32)          | 0.57 |
| **% LNs Involved**                    | 8% (1.6-20)       | 6% (1.5-56)       | 0.69 |
| **Extranodal Extension**              | 20 (54)           | 17 (47)           | 0.56 |
| **Perineural Invasion**               | 25 (68)           | 6 (18)            | <0.01|
| **Lymphovascular Invasion**           | 18 (51)           | 15 (43)           | 0.47 |
| **AJCC Pathologic Stage**             |                   |                   |      |
| 1-3                                   | 11 (30)           | 11 (31)           | 0.94 |
| 4                                     | 26 (70)           | 35 (69)           |      |
| **Interval, Resection to RT**         | 45.5 days (27-117)| 47.5 days (33-77) | 0.55 |
| **Interval, RT Start to End**         | 46 days (31-111)  | 46.5 days (34-60) | 0.70 |
| **RT Dose**                           | 6600 cGy (5000-6996) | 6600 cGy (5000-7200) |      |
| **Concurrent Chemotherapy**           | 11 (30)           | 15 (42)           | 0.29 |
| OTT                                   | 94 days (69-185)  | 93 days (74-120)  | 0.69 |

HPV: human papillomavirus; PET/CT: positron emission tomography/computed tomography; AJCC: American Joint Commission on Cancer; LNs: lymph nodes; RT: radiotherapy; OTT: overall treatment time.
Table 3: Univariable analysis of demographic, clinical, and pathologic variables for DFS and OS.

|                          | DFS                  |                      | OS                   |                      |
|--------------------------|----------------------|----------------------|----------------------|----------------------|
|                          | HR (95% CI)          | p                    | HR (95% CI)          | p                    |
| **Age**                  |                      |                      |                      |                      |
| Age                      | 0.99 (0.95-1.02)     | 0.40                 | 1.01 (0.97-1.05)     | 0.63                 |
| **Gender**               |                      |                      |                      |                      |
| Female                   | 1.30 (0.52-3.22)     | 0.57                 | 1.11 (0.47-2.59)     | 0.81                 |
| **Primary Site**         |                      |                      |                      |                      |
| Oral Cavity              | 5.77 (1.93-17.24)    | <0.01                | 4.62 (1.71-12.44)    | <0.01                |
| **Tobacco Use History**  |                      |                      |                      |                      |
| None                     | Ref                  | -                    | Ref                  | -                    |
| ≤10 pack-years           | 1.05 (0.36-3.07)     | 0.93                 | 1.61 (0.43-6.02)     | 0.48                 |
| >10 pack-years           | 2.05 (0.59-7.11)     | 0.26                 | 1.65 (0.60-4.57)     | 0.33                 |
| **PET/CT Staging**       |                      |                      |                      |                      |
| PET/CT Staging           | 1.32 (0.53-3.27)     | 0.55                 | 1.30 (0.57-3.01)     | 0.53                 |
| **Clinical AJCC Stage**  |                      |                      |                      |                      |
| 1-2                      | Ref                  | -                    | Ref                  | -                    |
| 3                        | 1.32 (0.44-3.92)     | 0.62                 | 0.88 (0.31-2.49)     | 0.81                 |
| 4a                       | 3.89 (1.41-10.76)    | <0.01                | 2.86 (1.13-7.19)     | 0.03                 |
| **HPV Negative**         |                      |                      |                      |                      |
| HPV Negative             | 7.42 (2.17-25.30)    | <0.01                | 5.43 (1.85-16.00)    | <0.01                |
| **Interval, Biopsy to Resection** | 1.02 (0.99-1.04)     | 0.24                 | 1.02 (1.00-1.04)     | 0.12                 |
| **Tumor Grade**          |                      |                      |                      |                      |
| 1-2                      | Ref                  | 0.06                 | Ref                  | <0.01                |
| 3                        | 2.65 (0.97-7.24)     | 0.06                 | 4.10 (1.40-11.97)    | 0.03                 |
| **Tumor Size**           |                      |                      |                      |                      |
| Tumor Size               | 1.52 (1.17-1.98)     | <0.01                | 1.29 (1.03-1.63)     | 0.03                 |
| Pathologic Nodal Tumor Size (largest) | 0.72 (0.47-1.11)     | 0.14                 | 0.84 (0.59-1.19)     | 0.33                 |
| # LNs Involved           | 0.95 (0.78-1.16)     | 0.60                 | 1.03 (0.97-1.10)     | 0.35                 |
| % LNs Involved           | 0.15 (0.00-32.51)    | 0.48                 | 1.10 (0.07-18.59)    | 0.95                 |
| **Extranodal Extension** |                      |                      |                      |                      |
| Extranodal Extension     | 1.31 (0.55-3.11)     | 0.54                 | 1.09 (0.49-2.40)     | 0.83                 |
| **Perineural Invasion**  |                      |                      |                      |                      |
| Perineural Invasion      | 2.12 (0.88-5.14)     | 0.10                 | 1.82 (0.81-4.07)     | 0.14                 |
| **Lymphovascular Invasion** | 1.24 (0.51-3.01)     | 0.63                 | 0.97 (0.43-2.16)     | 0.93                 |
| **Final Primary Margin Close (<1 mm) or Positive** | 1.07 (0.45-2.55)     | 0.87                 | 2.24 (1.01-4.95)     | 0.05                 |
| **AJCC Pathologic Stage** |                      |                      |                      |                      |
| 1-3                      | Ref                  | 0.58                 | Ref                  | 0.52                 |
| 4                        | 1.29 (0.52-3.20)     | 0.58                 | 1.31 (0.57-2.97)     | 0.52                 |
| **No Concurrent Chemotherapy** | 1.19 (0.48-2.95)     | 0.71                 | 0.95 (0.40-2.24)     | 0.91                 |
| **Interval, Resection to RT** | 1.03 (1.01-1.05)     | 0.01                 | 1.00 (0.97-1.04)     | 0.90                 |
| **Interval, RT Start to End** | 1.03 (1.01-1.06)     | 0.02                 | 1.01 (0.98-1.03)     | 0.62                 |
| **OTT**                  | 1.02 (1.01-1.04)     | <0.01                | 1.01 (0.99-1.02)     | 0.37                 |

DFS = disease-free survival; OS = overall survival; PET/CT = positron emission tomography/computed tomography; AJCC = American Joint Commission on Cancer; HPV = human papillomavirus; LNs = lymph nodes; RT = radiotherapy; OTT = overall treatment time. *Denotes integral units (i.e., 1 year for age, 1 day for intervals including OTT, 1cm for tumor and LN size, 1 LN for number of LNs involved, and 1% for percent LNs involved).

Table 4: Multivariable analysis of DFS and OS by HPV status and OTT.

|                          | DFS                  |                      | OS                   |                      |
|--------------------------|----------------------|----------------------|----------------------|----------------------|
|                          | HR (95% CI)          | p                    | HR (95% CI)          | p                    |
| **HPV Negative**         |                      |                      |                      |                      |
| HPV Negative             | 6.56 (1.89-22.79)    | <0.01                | 5.35 (1.80-15.85)    | <0.01                |
| **OTT**                  | 1.02 (1.00-1.03)     | 0.04                 | 1.00 (0.99-1.02)     | 0.77                 |

*Unit = 1 day.
Impact of OTT on HPV-Associated HNSCC

Discussion

Prior studies evaluating the impact of the interval from surgery to adjuvant radiotherapy on disease control and survival for HNSCC were performed prior to the reported rise of HPV-associated disease [1-5]. To our knowledge, the present study represents the first analysis of the impact of OTT in the context of HPV-associated disease. The demographic characteristics, primary site distribution, and treatment outcomes for HPV-associated disease within the study population are consistent with previously published reports [7-9]. Hence, the present study population is representative of surgically-managed HNSCC involving oropharyngeal and oral cavity subsites in the population at large.

It is noteworthy, albeit unsurprising that HPV association remained the most critical factor associated with DFS, DSS, and OS endpoints; however, OTT remained significantly associated with DFS in the multivariable analysis. While the OTT interval of 100 days was selected for illustrative purposes and has been employed in a previous OTT study, this should not be seen as a specific threshold [4]. Rather, the data demonstrate a gradient rather than a threshold effect, with the present study suggesting a 2% increase in risk of recurrence for each day of OTT prolongation.

OTT prolongation may be attributable to a longer interval from resection to RT initiation or a prolonged course of RT (initiation to completion).

The previous series of definitive RT for HNSCC have demonstrated the adverse impact of the latter on disease control and survival [1, 17-20]. Further, the reduction of the adjuvant RT interval via accelerated fractionation has demonstrated a modest improvement in outcomes [21]. Specific to our own series, increases in either time from resection to RT initiation or from RT initiation to completion were associated with diminished cancer control. As contemporary head and neck radiotherapy treatment planning may require 7-10 days from simulation to treatment initiation, we recommend preoperative consultation with radiation and medical oncologists, as well as early postoperative multidisciplinary evaluation, in order to expedite care and optimize outcomes.

While OTT remained significantly associated with DFS, independent of HPV-association, the magnitude of impact specific to HPV positive or negative subgroups remains to be determined. Preliminary data suggest that HPV-associated tumors are particularly radiosensitive, with several ongoing investigations seeking methods to de-intensify treatment in this subpopulation (e.g., dose reduction) [9]. Larger subsets will be required to report on relative differences in the impact of OTT on HPV positive or negative subgroups.

The rise of HPV-associated HNSCC has been most pronounced in patients with limited tobacco or alcohol exposure, particularly males [7, 8]. These tumors have a high predilection for the oropharynx but are also noted in the oral cavity and other upper aerodigestive tract subsites [7]. We elected to focus on the oral cavity and oropharyngeal sites in our...
study for several reasons. First, surgery remains a primary intervention for both of these subsites. Second, the study populations from prior investigations of OTT were primarily composed of oropharyngeal and oral cavity subsites [4, 21]. Third, within our intra-institutional database, pathologic immunohistochemistry- (p16) or DNA-based HPV data was only available for oropharyngeal and oral cavity subsites during the study period.

### Conclusion

The present study supports previous findings that HPV-associated HNSCC is associated with improved DFS, DSS, and OS. Further, the findings suggest that OTT remains significantly associated with DFS in the setting of HPV-associated disease. While these data require validation in a larger series, efforts should be made to optimize the interval from resection to adjuvant RT completion.

### Funding

None.

### Conflicts of Interest

None.

### REFERENCES

1. Robertson C, Robertson AG, Hendry JH, Roberts SA, Slevin NJ et al. (1998) Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. J Int Radiat Oncol Biol Phys 40: 319-329. [Crossref]
2. Vikram B (1979) Importance of the time interval between surgery and postoperative radiation therapy in the combined management of head and neck cancer. Int J Radiat Oncol Biol Phys 5: 1837-1840. [Crossref]
3. Byers RM, Clayman GL, Guilamondequi OM, Peters LJ, Goepfert H (1992) Resection of advanced cervical metastasis before definitive radiotherapy for primary squamous carcinomas of the upper aerodigestive tract. Head Neck 14: 133-138. [Crossref]
4. Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA et al. (2002) Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 24: 115-126. [Crossref]
5. Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C (2000) Importance of overall treatment time for the resection to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 25: 313-319. [Crossref]
6. Decker J, Goldstein JC (1982) Risk factors in head and neck cancer. N Eng J Med 306: 1151-1155. [Crossref]
7. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33: 3235-3242. [Crossref]
8. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF et al. (2007) Lack of association of alcohol and tobacco with HPV16 associated head and neck cancer. J Natl Cancer Inst 99: 1801-1810. [Crossref]
9. Lindel K, Beer KT, Laissae J, Greiner RH, Aebersold DM (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805-813. [Crossref]
10. Gillison ML, Kock WM, Capone RB, Spafford M, Westra WH et al. (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 747-753. [Crossref]
11. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M et al. (2002) Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8: 3187-3192. [Crossref]
12. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck Wikland E et al. (2000) Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89: 300-304. [Crossref]
13. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ et al. (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90: 1626-1636. [Crossref]
14. Li W, Thompson CH, O’Brien CJ, McNeil EB, Scolyer RA et al. (2003) Human papillomavirus positivity predicts favourable outcomes for squamous carcinoma of the tonsil. Int J Cancer 106: 553-558. [Crossref]
15. Wittekindt C, Gultekin E, Weissenbom SJ, Dienes HP, Pfister HJ et al. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and its implications on survival. Adv Otorhinolaryngol 2005 62: 72-80. [Crossref]
16. Greene FL, Page DL, Fleming ID (2009) AJCC Cancer Staging Manual, 7th Edition: Head and Neck Sites. The American Joint Committee on Cancer.
17. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA et al. (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7-16. [Crossref]
18. Van den Bogaert W, van der Leest A, Rijnders A, Delaere P, Thames HD et al. (2000) Human papillomavirus infection. Int J Radiat Oncol Biol Phys 48: 7-16. [Crossref]
19. Van den Bogaert W, van der Leest A, Rijnders A, Delaere P, Thames H et al. (1995) Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol 36: 177-182. [Crossref]
20. Andur RJ, Parsons JT, Mendenhall WM, Millon RR, Cassisi NJ (1989) Split course versus continuous-course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 17: 279-285. [Crossref]
21. Hendry JH (1992) Treatment acceleration in radiotherapy: the relative time factors and dose-response slopes for tumours and normal tissues. Radiother Oncol 25: 308-312. [Crossref]
22. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL et al. (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51: 571-578. [Crossref]